Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

CARLSBAD, Calif., Nov. 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.  Isis will develop both ISIS-GCGRRx and ISIS-GCCRRx to treat a broad population of diabetic patients.  The unique mechanism of action of these new drugs could allow each drug to be used in combination with other therapies for type 2 diabetes.

"Type 2 diabetes is a progressive disease.  More than half of all diabetic patients cannot reach acceptable glucose control with currently available therapies.  Our goal is to develop safe, effective drugs with unique mechanisms of action that can provide significant therapeutic benefit," said B. Lynne Parshall, Chief Operating Officer, Chief Financial Officer and Secretary of Isis. "This year we have made significant progress toward this goal.  Our ISIS-GCGRRx and ISIS-GCCRRx drugs are designed to reduce the activity of two critical hormones that oppose the action of insulin and cause increased glucose levels in diabetic patients.  The initial clinical development for both of these drugs will focus on treating diabetic patients with moderate to severe diabetes who cannot achieve adequate glucose control with existing treatments.  We believe that each drug could address a significant commercial market by providing long-term disease control in such patients."

ISIS-GCGRRx targets the glucagon receptor (GCGR) to reduce the effects of glucagon, a hormone that causes glucose production in the liver.  Reducing GCGR also increases the production of active glucagon-like peptide (GLP-1), a hormone that preserves pancreatic function and enhances insulin secretion. "Glucagon plays a particularly significant role in increasing blood glucose levels
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Saint-Gobain has acquired ZenPure, ... filtration products, mainly for the life sciences sector. ... in a state-of-the-art plant in Hangzhou, China ... the globe and will bolster the range of fluid ... acquisition is fully in line with the Group,s strategy ...
(Date:5/6/2015)...  Membership in Medicare Supplement plans continued to ... Strategy report released by Mark Farrah Associates (MFA).  ... Med Supp plans, covered approximately 11.2 million seniors ... from 2013. Between 2013 and 2014, enrollment in ... Though UnitedHealth was the segment growth leader, many ...
(Date:5/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/7qn2gf/global_insulin ) ... Insulin Patch Market Opportunity Analysis" report to ... ultrasound and iontophoresis are being used for the ... type of technique, their prices may vary which ... In long-term, it would be considered as inexpensive ...
Breaking Medicine Technology:Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Insulin Patch Market Opportunity Analysis 2015 2
(Date:5/6/2015)... (PRWEB) May 07, 2015 Device Patent Law ... 2015 — 11:00 a.m. – 12:30 p.m. EDT, http://www.fdanews.com/DevicePatentLaw ... in expensive patent lawsuits and claims that waste their time. ... of these cases could be prevented if devicemakers better understand ... latest court rulings and revisions to patent laws from all ...
(Date:5/6/2015)... 2015 As the exclusive hospital of the ... the Pirate Ship at Raymond James Stadium for all the ... first to be drafted into the “Bucs Babies” program last ... spend time with children, particularly those born at the Florida ... be Buccaneers fans. I really enjoyed my time participating in ...
(Date:5/6/2015)... 06, 2015 On April 27, 2015, ... Plastic Surgery ,” compiled quotes about cosmetic surgery from ... pop singer Iggy Azalea, and Gwyneth Paltrow. For the ... having plastic surgery themselves; only a couple ... its expectations of youth and beauty. (see: goo.gl/wSomih) , ...
(Date:5/6/2015)... Chesapeake, Va. (PRWEB) May 06, 2015 ... hospital in the state of Virginia to acquire ... Vinci® surgical robot. The system upgrade includes enhanced ... many minimally invasive procedures across a wide spectrum ... surgical options, reduced pain and quicker recovery times. ...
(Date:5/6/2015)... King of Prussia, PA (PRWEB) May 06, 2015 ... Business Process Outsourcing solutions to the Medicare Advantage, Medicare ... three finalists in the Continuity and Resilience Team category ... by the Business Continuity Institute to recognize the outstanding ... or operating in the North America Region, including the ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 2Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 3Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... CHICAGO, Jan. 26 The YMCA of Metropolitan Chicago ... residents to lead healthier lifestyles.According to the U.S. Department ... report they are not physically active. Poor diet and ... are overweight or obese are at increased risk for ...
... warm up chilly Chicago bus riders by heating ten bus shelters in the downtown area. ... following locations:, , 16 South ... @ Lake , 300 North Michigan Avenue @ Wacker ... 757 North Michigan Avenue @ Chicago , ...
... glucose scored worse on cognition tests, study found , , MONDAY, ... diabetes, higher average blood glucose (sugar) levels may be linked ... Researchers found that patients with higher levels of hemoglobin A1C ... 3 months) had significantly worse results while doing cognitive tasks ...
... an uncommon, but possible, reaction, study finds, , , ... take medications for attention-deficit hyperactivity disorder (ADHD) may ... hallucinations. , U.S. government experts reviewed clinical ... the commonly prescribed ADHD stimulant medications, such as ...
... Ill., Jan. 26 /PRNewswire/ -- Alma ... and radiofrequency-based aesthetic devices, announced today the FDA ... The UniForm is the fifth module available ... UniForm has received FDA clearance for "the temporary ...
... Prevent serious injuries from ,extreme, winter sports by following ... For many thrill-seekers, extreme ("x-treme") sports can be a ... long winter months. Recently televised events such as the ... sports, including downhill ski racing and jumping, snowboarding, snowmobiling, ...
Cached Medicine News:Health News:YMCA and Dominick's Offer Health and Wellness Options 2Health News:It's Cold Outside! Warm Up in Select Downtown Chicago Heated Bus Shelters Courtesy of TYLENOL(r) Warming Liquids 2Health News:Higher Blood Sugar Could Impair Thinking 2Health News:Hallucinations Are Rare Side Effects of ADHD Medications 2Health News:'X-Tremely' Dangerous Sports 2Health News:'X-Tremely' Dangerous Sports 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: